SCHEMBL1316896

SCHEMBL1316896

Cc1ccccc1-c1ccc(C(=O)OC(C)(C)C)c(NC(=O)c2cc(N3CCCCC3)ccc2O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.42
ALDH1A1 P00352 5/20 0.42
GAA P10253 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
MAPK1 P28482 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
ATM Q13315 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
MCL1 Q07820 2/20 0.40
BRPF1 P55201 1/20 0.40
RXFP1 Q9HBX9 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12117977 0.93 MAPT (0.46) MAPTALDH1A1GAAL3MBTL1NPC1
SCHEMBL1319038 0.90 RXFP1 (0.47) MAPTGAANPC1RAB9ASMN1; SMN2
SCHEMBL1316253 0.89 HDAC1 (0.44) MAPTALDH1A1GAAL3MBTL1NPC1
SCHEMBL1317178 0.87 MCL1 (0.52) MAPTALDH1A1GAAL3MBTL1NPC1
SCHEMBL1316408 0.86 LRRK2 (0.53) KMT2AMEN1
SCHEMBL12117571 0.85 RXFP1 (0.47) MAPTALDH1A1GAAL3MBTL1NPC1
SCHEMBL1316838 0.84 HDAC3 (0.44) MAPTNPSR1MAPK1HDAC1HDAC2
SCHEMBL12117784 0.84 MAPT (0.45) MAPTALDH1A1GAAL3MBTL1NPC1
SCHEMBL12166086 0.84 MAPT (0.45) MAPTALDH1A1GAAL3MBTL1NPC1
SCHEMBL1316071 0.83 BACE1 (0.44) MAPTALDH1A1GAAL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 MAPT 4045/4885ALDH1A1 813/4885GAA 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.